Melinta Therapeutics - MNLT Continued Breakout

Possible Continuation into March 12th earnings .

*Expected quarterly revenues up 320%.
*Short interest has decreased 50.2% since mid December.
*Average daily volume is up 19% over the past 4 days.
*NDA filing for Baxdela Phase 3 data 1H 2019

Entry Points: 1.32-1.45
Price Targets: 1.74---2.00---2.26---2.43
Tight Stop-Loss at 1.25

Company Info
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Help Center Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing TradingView Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out